MARKER THERAPEUTICS (MRKR)
(Delayed Data from NSDQ)
$4.29 USD
-0.08 (-1.72%)
Updated Apr 26, 2024 03:58 PM ET
After-Market: $4.42 +0.13 (3.03%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
MRKR 4.29 -0.08(-1.72%)
Will MRKR be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for MRKR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MRKR
MARKER THERAPEUTICS, INC. (MRKR) Reports Q3 Loss, Tops Revenue Estimates
MRKR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for MRKR
Marker Therapeutics’ MT-601 Shows Promising Results
Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic MalignanciesÂ
Marker Therapeutics announces presentation on Phase 1 APOLLO study
Marker Therapeutics GAAP EPS of -$1.59, revenue of $3.31M
Marker Therapeutics Advances in Immuno-Oncology